A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009656/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to compare the efficacy and safety of 2 starting doses of
ponatinib compared to nilotinib in participants with imatinib-resistant chronic myeloid
leukemia (CML) in chronic phase (CP).
提供机构：
Vivli
创建时间：
2023-12-21
